VRAX Stock Analysis: Buy, Sell, or Hold?
VRAX - Virax Biolabs Group Limited Ordinary Shares
$1.24
-0.10 (-7.46%)
▼
5d:
-23.47%
30d:
-51.37%
90d:
-61.13%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 01, 2026
0d
Get Alerted When VRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VRAX is down 23.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VRAX is down 23.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VRAX is currently trading at $1.24, which is considered oversold relative to its 30-day fair value range of $1.65 to $2.50.
Technical Outlook: Technically, VRAX is in a downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1765.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRAX is in a downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1765.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.65 -
$2.50
Company Quality Score
46/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 1765.7% below Wall St target ($25.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.65 -
$2.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.32
Resistance Level
$2.13
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.22
Wall Street Target
$25.00
(+1765.7%)
Revenue Growth (YoY)
684.9%
Share & Embed Analysis
Last updated: October 22, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 73 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 63 BUY |
